期刊文献+

外周血中BAFF、BAFF-R及Bcl-xL的表达与B细胞非霍奇金淋巴瘤疾病进展的相关性研究 被引量:1

Correlation between expressions of BAFF,BAFF-R and Bcl-xL in peripheral blood and progression in B cell non-Hodgkin′s lymphoma patients
原文传递
导出
摘要 目的研究B细胞性非霍奇金淋巴瘤(B-NHL)患者外周血B cell-activating factor(BAFF)、其受体BAFF-R及Bcl-xL基因的表达,探讨其与B-NHL疾病进展的相关性。方法应用实时荧光定量PCR法检测36例B-NHL患者外周血单个核细胞(PBMC)BAFF、BAFF-R、Bcl-xL mRNAs的相对表达水平,以7例健康献血员作为对照,并据性别、淋巴瘤国际预后指数(IPI)、年龄、临床分期、是否耐药进行分组比较。结果 B-NHL患者PBMC BAFF、BAFF-R及Bcl-xL的mRNAs表达较正常对照组显著升高(P<0.05),Ⅲ/Ⅳ期高于Ⅰ/Ⅱ期,耐药B-NHL组高于非耐药组(P<0.05)。结论外周血单个核细胞BAFF、BAFF-R、Bcl-xL mRNAs的表达水平与B-NHL临床分期有关,在耐药B-NHL外周血中明显升高,提示BAFF/BAFF-R介导的信号通路可能参与B-NHL的临床进展及耐药机制。 Objective To detect the expressions of BAFF,BAFF-R and Bcl-xL in peripheral blood from patients with B cell non-Hodgkin′s lymphoma(B-NHL),and to investigate the correlation between the level of these genes and the progression of B-NHL.Methods The expression of BAFF,BAFF-R and Bcl-xL in peripheral blood mononuclear cells(PBMC) from patients(n=36) and healthy volunteers(n=7) was examined via real-time fluorescence quantitative polymerase chain reaction(real-time q-PCR) at the mRNAs level.These data were further analyzed according to gender,lymphoma international prognostic index(IPI),age,clinical staging and drug resistance.Results The expressions of BAFF,BAFF-R and Bcl-xL were significantly increased in PBMC from patients with B-NHL compared with control group(P0.05).The expression of these genes in groups of stage Ⅲ/Ⅳ and the resistant B-NHL was respectively higher than that of stageⅠ/Ⅱ and non resistant B-NHL groups(P0.05).Conclusion The expression of BAFF,BAFF-R and Bcl-xL in PBMC from patients with resistant B-NHL is significantly increased,correlated with the B-NHL clinical staging.These results suggest that BAFF/BAFF-R mediated signal pathway is involved in the progression of B-NHL and drug resistance.
出处 《军事医学》 CAS CSCD 北大核心 2012年第3期209-212,共4页 Military Medical Sciences
基金 国家自然科学基金资助项目(81071945 30873030)
关键词 B细胞性非霍奇金淋巴瘤 耐药性 肿瘤 基因表达 BAFF BAFF-R BCL-XL B细胞激活因子 受体 B细胞活化因子 B cell non-Hodgkin′s lymphoma drug resistance neoplasm gene expression BAFF BAFF-R Bcl-xL B-cell activating factor receptor B-cell activating factor
  • 相关文献

参考文献14

  • 1Dalle S,Dupire S,Bninet-Manquat S. In vivo model of follicular lymphoma resistant to rituximab[J].Clinical Cancer Research,2009,(03):851-857.doi:10.1158/1078-0432.CCR-08-1685.
  • 2Jazirehi AR,Vega MI,Bonavida B. Development of rituximab-resist-ant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy[J].Cancer Research,2007,(03):1270-1281.
  • 3Novak AJ,Grate DM,Stenson M. Expression of Blys and its receptors in B-cell non-Hodgkin lymphoma:correlation with disease activity and patient outcome[J].Blood,2004,(08):2247-2253.
  • 4Ansell SM,Novak AJ,Ziesmer S. Serum BlyS levels increase after rituximab as initial therapy in patients with follicu-lar grade 1 non-Hodgkin lymphoma[J].American Journal of Hematology,2009,(02):71-73.doi:10.1002/ajh.21328.
  • 5Briones J,Timmerman JM,Hilbert DM. BlyS and BlyS receptor expression in non-Hodgkin's lymphoma[J].Exp Hema-tol,2002,(02):135-141.
  • 6MoreauxJ,Legouffe E,Jourdan E. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone[J].Blood,2004,(08):3148-3157.
  • 7Kem C,Comuel JF,Billard C. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an auto-crine pathway[J].Blood,2004,(02):679-688.
  • 8Mackay F,Browning JL. BAFF:a fundamental survival factor for B cells[J].Nature Reviews Immunology,2002,(07):465-475.
  • 9Mackay F,Ambrose C. The TNF family members BAFF and APRIL; the growing complexity[J].Cytokine & Growth Factor Reviews,2003,(3-4):311-324.
  • 10Mackay F,Schneider P,Rennert P. BAFF and APRIL:a tutorial on B cell survival[J].Annual Review of Immunology,2003,(19):231-264.

二级参考文献15

  • 1Mackay F, Browning J L. BAFF: a fundamental survival factor forBcells[J]. Nat Rev Immunol, 2002,2(7) :465--475.
  • 2Mackay F, Ambrose C. The TNF family members BAFF and APRIL:the growing complexity [J]. Cytokine Growth Factor Rev, 2003,14(3--4):311--324.
  • 3Mackay F, Schneider P, Rennert P, et al. BAFF and APRIL: a tutorialon B cell survival[J]. Annu Rev Immunol,2003,21(19) : 231--264.
  • 4Moore P A, Belvedere O, Orr A, et al. Blys:member of the tumor necrosis factor family and B lymphocyte stimulator[J].Science, 1999, 285(5425) :260--263.
  • 5Briones J, Timmerman J M, Hilbert D M, et al. BlyS and BlyS receptor expression in non-Hodgkin, s lymphoma[J]. Exp Hematol, 2002,30(2) : 135-- 141.
  • 6Moreaux J,Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone[J]. Blood, 2004,103(8):3148--3157.
  • 7Kern C, Cornuel J F, Billard C, et al.Involvement of BAFF and APRIL in she resistance so apoptosis of B-CLL through an autocrine pathway[J].Blood, 2004,103 (2) : 679-- 688.
  • 8Shaffer A L, Rosenwald A, Staudt L M. Lymphoid malignancies: the dark side of B-cell differentiation[J]. Nat Rev Immunol, 2002,2(12):920--932.
  • 9Shu H, Johnson H. B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1[J].Proc Natl Acad Sci USA, 2000, 97(16).- 9156--9161.
  • 10Yu G, Boone T, Delaney J, et al. APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immuneity[J]. Nat Immunol,2000,1(3) :252--256.

同被引文献19

  • 1Jellusova J, Miletic AV, Cato MH, et al. Context-specific BAFF-R signaling by the NF-K B and PI3K pathways[J]. Cell Rep, 2013, 5(4): 1022- 1035.
  • 2Kry T Fkova O, Helmers S, Venalis P, et al. Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies [J]. Arthritis Res Ther, 2014, 16 (5): 454.
  • 3Peng Y, Chen X, Liu Q, et al. Alteration ofna?ve and memory B-cell subset in chronic graft-versus-host disease patients after treatment with mesenchymal stromal cells [J]. Stem Cells Transl Med, 2014, 3 (9): 1023-1031.
  • 4Xu H, Dong P, He X, et al. B-cell-activating factor code and human cytomegalovirus infection in renal transplant recipients [J]. Microbiol Immtmol, 2014, 58(8): 439-448.
  • 5Hildebrand JM, Luo Z, Manske MK, et al. A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling[J]. J Exp Med, 2010, 207 (12): 2569-2579.
  • 6Pham LV, Fu L, Tamayo AT, et al. Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-K B-inducing kinase while activating both canonical and alternative nuclear factor-K B pathways [J]. Blood, 2011, 117 (1): 200-210.
  • 7Gardam S, Turner VM, Anderton H, et al. Deletion of clAPI and cIAP2 in murine B lymphocytes constitutively activates cell survival pathways and inactivates the germinal center response [J]. Blood, 2011, 117(15): 4041-4051.
  • 8Razani B, Zamegar B, Ytterberg AJ, et al. Negative feedback in noncanonical NF-kappaB signaling modulates NIK stability through IKKalpha-mediated phosphorylation [J]. Sci Signal, 2010, 3 (123): ra41.
  • 9Zhu Y, Liu Y, Qian Y, et al. Research on the efficacy of Celastrus Orbiculatus in suppressing TGF-betal-induced epithelial-mesenchy- real transition by inhibiting HSP27 and TNF-alpha-induced NF- kappaB/Snail signaling pathway in human gastric adenocarcinoma[J]. BMC Complement Altern Med, 2014, 14(1): 433.
  • 10秦琼,常艳,吴育晶,魏伟.B淋巴细胞刺激因子及其受体介导的免疫细胞信号转导[J].中国药理学通报,2011,27(5):593-596. 被引量:2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部